Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: HER-2 Positive Breast Cancer|Metastatic Malignant Neoplasm to Brain
Interventions: DRUG: Tesevatinib|DRUG: Trastuzumab
Sponsor: Kadmon Corporation, LLC